-- 据彭博社周四发布的一份分析报告显示，受伊朗战争影响，美国汽油价格飙升，加州汽油价格突破每加仑6美元，中西部地区汽油价格达到每加仑4.67美元，柴油价格接近每加仑7.50美元。 该分析报告指出，继亚洲和欧洲油价连续数周上涨后，美国各地的燃油价格也大幅攀升，与冲突相关的能源冲击持续在全球市场蔓延。 该分析报告援引美国汽车协会（AAA）的数据称，加州普通汽油的平均价格周三超过每加仑6美元，创下自2023年10月以来的最高水平。 该分析报告还指出，伊利诺伊州汽油价格达到每加仑4.67美元，比去年平均水平高出1美元多；印第安纳州、密歇根州和俄亥俄州等地区市场也出现了类似的油价飙升。 该分析报告显示，柴油价格与汽油价格同步上涨，加州柴油价格接近每加仑7.50美元，中西部地区柴油价格则维持在每加仑5美元左右。 分析显示，美国汽油期货价格升至近四年来的最高水平。 分析指出，伊朗冲突已进入第九周，交易员们越来越担心霍尔木兹海峡（一条重要的石油运输通道）会长期中断或被封锁。 分析还指出，燃油价格上涨正成为共和党在中期选举前面临的政治挑战，尤其是在密歇根州和俄亥俄州的参议院选举中。 分析称，加州油价飙升给州长加文·纽森带来了压力，他可能考虑参加2028年总统竞选。 分析援引伍德麦肯兹的数据显示，中西部炼油厂的运营问题加剧了供应紧张，其中包括埃克森美孚位于乔利埃特的炼油厂一个关键加工装置的停产。 分析指出，英国石油公司位于印第安纳州怀廷的炼油厂发生的另一起电力中断事件，即使其他设施仍在运行，也加剧了不确定性，导致区域燃油价格持续波动。
Related Articles
Mining & Metals
Agnico Eagle Q1 Record Adjusted Net Income of U$1,706 million or $3.41 per share
$AEM.TO
Treasury
TD Bank Group Issues 150 Million Swiss francs Green Bond
Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.
$TD$TD.TO
Research
Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.
$AMGN